(56 days)
No
The summary describes passive fiducial markers used for localization, with no mention of AI/ML in the intended use, device description, or any other section.
No.
The device is described as "Ball Fiducial Markers" used for visualization and localization in stereotactic radiosurgery and radiotherapy, which are treatment modalities, but the markers themselves are diagnostic/localization tools, not therapeutic in nature. They do not directly treat the disease; rather, they aid in guiding treatment.
No
This device is a fiducial marker used for target localization during stereotactic radiosurgery and radiotherapy, which is a treatment modality, not a diagnostic one.
No
The device description explicitly states it is a physical implantable device ("Ball Fiducial Markers are intended to be implanted into the body").
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the markers are "intended to be implanted into the body" for visualization and localization during radiosurgery and radiotherapy. This is an in vivo application (within the living body).
- IVD Definition: In Vitro Diagnostics (IVDs) are medical devices used to examine specimens taken from the human body, such as blood, urine, or tissue, to provide information about a person's health. This is an in vitro application (outside the living body).
The function of these fiducial markers is to be physically present within the patient's body to aid in imaging and treatment planning, which is the opposite of how IVDs function.
N/A
Intended Use / Indications for Use
The Ball Fiducial Markers are intended to be implanted into the body to accurately visualize and constitute the reference frame for stereotactic radiosurgery and radiotherapy target localization. Specifically, they can be used in intracranial diseases such as gliomas, neuromas, meningiomas, astrocytomas, arteriovenous malformations, and metastatic carcinomas. Additionally, they can be used in the body for treating hepatic, pancreatic, retroperitoneal, paraspinal, skeletal, prostatic and breast tumors.
Product codes
IYE
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Intracranial (gliomas, neuromas, meningiomas, astrocytomas, arteriovenous malformations, and metastatic carcinomas), hepatic, pancreatic, retroperitoneal, paraspinal, skeletal, prostatic and breast.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
.
K 1.0 113)
JUN 1 7 2010
510(k) Summary
Applicant / Manufacturer: Cosman Medical, Inc. 76 Cambridge St., Burlington MA 01803. USA Tel. 781-272-6561, Fax 781-272-6563
Fiducial Markers
April 19, 2010
CFR 892.5050.
system Product Code: IYE
Contact Person:
Louis Falcone, Director of RA LFalcone@cosmanmedical.com
Registration Number: 3004867882
Date Prepared: April 19, 2010
Trade Names:
Dated:
Common Name:
Classification:
Performance Standard:
No applicable performance standards have been issued under section 514 or under section 513(b) of the Food, Drug, and Cosmetic Act.
CIVCO MEDICAL SOLUTIONS、Fiducial Markers
Class II, Medical charged-particle radiation therapy
COSMAN MEDICAL Ball Fiducial Markers
Predicate Device:
-- (K071614)
Intended Use:
The Ball Fiducial Markers are intended to be implanted into the body to accurately visualize and constitute the reference frame for stereotactic radiosurgery and radiotherapy target localization. Specifically, they can be used in intracranial diseases such as gliomas, neuromas, meningiomas, astrocytomas, arteriovenous malformations, and metastatic carcinomas. Additionally, they can be used in the body for treating hepatic, pancreatic, retroperitoneal, paraspinal, skeletal, prostatic and breast tumors.
Comparison to Predicate:
The Cosman Ball Fiducial Markers have been compared to previously 510(k) cleared devices with respect to intended use and technological characteristics. The Cosman Ball Fiducial Markers have similar physical and technical characteristics to the predicate devices. The technical characteristic comparison chart provided in this 510(k)
Cosman Ball Fiducial Markers 510(k) Page 3
1
notification shows that the Cosman Ball Fiducial Markers are substantially equivalent to the CIVCO MEDICAL SOLUTIONS, Fiducial Markers predicate device and are safe and effective for indicated intended use.
Safety and Effectiveness: The comparison to the predicate device demonstrates that the Cosman Ball Fiducial Markers are safe and effective and are substantially equivalent to the CIVCO MEDICAL SOLUTIONS Fiducial Markers predicate device.
Submitted By:
Name: Louis Falcone
Louis Idue
Signature
2
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird-like figure. The symbol is stylized with three distinct lines forming the body and wings.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
JUN 1 7 2010
Mr. Louis Falcone Director of RA Cosman Medical, Inc. 76 Cambridge Street BURLINGTON MA 01803
Re: K101131
Trade/Device Name: Cosman Ball Fiducial Markers Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: April 12, 2010 Received: April 22, 2010
Dear Mr. Falcone:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
3
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (2) CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a logal y marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Viro Diagnostic Device Evaluation and Safety at (30) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its the first nic (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Amed J. H.
Donald J. St.Pierre Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known): K (0113)
Device Name: Cosman Ball Fiducial Markers
Indications For Use:
"The Ball Fiducial Markers are intended to be implanted into the body to accurately visualize and constitute the reference frame for stereotactic radiosurgery and radiotherapy target localization. Specifically, they can be used in intracranial diseases such as gliomas, neuromas, meningiomas, astrocytomas, arteriovenous malformations, and metastatic carcinomas.
Additionally, they can be used in the body for treating hepatic, pancreatic, retroperitoneal, paraspinal, skeletal, prostatic and breast tumors."
Prescription Use X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE) Page 1 of
510K
(Division Sign-Off) Division of Radiological Devi Office of In Vitro Diagnostic Device Evalua
Cosman Ball Fiducial Markers 510(k) · Page 2